MCRB is expected to report earnings to rise 10.58% to -229 cents per share on August 05
Q2'26
Est.
$-2.30
Q1'26
Missed
by $1.93
Q4'25
Missed
by $1.59
Q3'25
Beat
by $0.98
Q2'25
Missed
by $2.18
The last earnings report on May 05 showed earnings per share of -207 cents, missing the estimate of -15 cents. With 135.37K shares outstanding, the current market capitalization sits at 54.23M.
A.I. Advisor
published General Information
General Information
a developer of novel treatments for diseases related to the human microbiome
A.I.dvisor indicates that over the last year, MCRB has been loosely correlated with ORMP. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if MCRB jumps, then ORMP could also see price increases.
MCRB's Stochastic Oscillator is staying in oversold zone for 1 day
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for MCRB's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The 10-day moving average for MCRB crossed bullishly above the 50-day moving average on July 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MCRB advanced for three days, in of 251 cases, the price rose further within the following month. The odds of a continued upward trend are .
MCRB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MCRB as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MCRB turned negative on July 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .
MCRB moved below its 50-day moving average on July 08, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCRB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for MCRB entered a downward trend on June 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.047) is normal, around the industry mean (22.746). P/E Ratio (12.217) is within average values for comparable stocks, (37.261). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.488). MCRB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (44.444) is also within normal values, averaging (432.117).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MCRB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MCRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
